Comparing Tamoxifen and Etoposide for Glioblastoma Recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to compare the effectiveness of two medications, tamoxifen and etoposide, in managing the first recurrence of glioblastoma multiforme (GBM) after initial treatment. It is a single-center, randomized phase II controlled study that will enroll patients who have histologically confirmed GBM and have shown progression after first-line chemoradiotherapy. Participants will be monitored for their response to either treatment, with the goal of determining which drug offers better outcomes for patients experiencing recurrence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically proven GBM with progression after previous first line chemoradiotherapy with temozolomide.
2. Progression documented by MRI with at least one bi-dimensionally measurable target lesion with one diameter of at least 10 mm, visible on two or more axial slices 5 mm apart.
3. Not received radiotherapy within the three months before the diagnosis of progression.
4. Stable or decreasing dose of corticosteroids prior to randomization: corticosteroids (dexamethasone) should be given at the lowest dose needed to control symptoms arising from increased intracerebral edema.
5. ECOG performance 0-2 (Appendix 2).
6. Age from 18-65 years.
7. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to the first dose of study treatment. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
8. Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.

   Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
9. Laboratory evaluation obtained within 7 days prior to randomization, with adequate function as defined below:

   * ANC ≥ 1.5 x 109/L
   * Platelets ≥ 100 x 109/L
   * Serum creatinine ≤ 1.5 times ULN
   * Total serum bilirubin ≤ 1.5 times ULN
   * ALT \< 3 times ULN
   * AST \< 3 times ULN
   * Alkaline phosphatase \< 3 times ULN
10. Patient must understand and sign an informed consent prior to study registration.

Exclusion Criteria:

1. History of another malignancy or a concurrent malignancy (exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
2. Uncontrolled hypertension (systolic blood pressure \>150 mm Hg or diastolic blood pressure \>100 mm Hg).
3. Any arterial or venous thrombosis up to 6 months before registration.
4. Evidence of recent hemorrhage on brain MRI.
5. Substantial cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\<6 months prior to enrollment), unstable angina, congestive heart failure (\> New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.

Where it's running

• Cross Cancer Institute
  Edmonton, Alberta, Canada Recruiting

Study contacts

• Study coordinator: Jacob Easaw, MD, PhD, FRCPC
• Email: jay.easaw@ahs.ca
• Phone: 780-432-8290

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Adding ruxolitinib to standard radiation and temozolomide for newly diagnosed glioblastoma

  This trial will try whether adding the oral drug ruxolitinib to standard radiation and temozolomide helps adults newly diagnosed with glioblastoma.

  Recruiting at 2 sites Phase 2 Baptist Health South Florida · Miami, Florida and 1 other locations · NCT06991101

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Using low-intensity magnetic therapy for newly diagnosed glioblastoma patients

  This study is testing whether a low-intensity magnetic therapy device can safely help people who have just been diagnosed with glioblastoma.

  Recruiting at 6 sites BioTex, Inc. · Stuttgart, Baden-Wurttemberg and 5 other locations · NCT06533163

• Evaluating Bevacizumab with Focused Ultrasound for Recurrent Glioblastoma

  This study is testing if adding focused ultrasound to the standard treatment of Bevacizumab can help people with recurrent glioblastoma feel better and live longer.

  Recruiting at 2 sites Phase 3 NaviFUS Corporation · Taipei and 1 other locations · NCT06496971

• Using FET-PET fused with MRI to better map and treat glioblastoma

  This will try using FET-PET combined with contrast MRI to better identify tumor tissue and guide surgery and treatment for adults with a single, newly diagnosed glioblastoma.

  Recruiting Copernicus Memorial Hospital · Lodz, Łódź Voivodeship · NCT06466031

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.